SCYNEXIS Secures Up to $214M BARDA Contract to Advance SCY-247 Antifungal
SCYX sits 34% above its 52-week low of $3.53 on elevated volume (30× avg).
Summary
SCYNEXIS signed a BARDA contract worth up to $214 million in non-dilutive funding to advance SCY-247, its second-generation antifungal, with an initial $18.5 million base period to fund a Phase 2 trial in invasive candidiasis.
Key Events · M&A and Partnerships · SCYX
-
BARDA Contract Signed
SCYNEXIS entered into an Award/Contract with BARDA on September 25, 2026, providing up to $214 million in non-dilutive funding to develop SCY-247, its second-generation fungerp antifungal candidate.
-
Initial $18.5M Base Period
The initial base period provides approximately $18.5 million to advance oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis.
-
Cost-Share Structure
The contract is a cost-share arrangement with BARDA supporting eligible SCY-247 costs, including direct and general and administrative expenses. SCYNEXIS expects to fund its share within its existing operating plan.
-
Up to 10-Year Extension
BARDA may exercise up to six options that could extend the contract term for up to ten years, potentially funding development through NDA submission for two indications: treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients.
Analysis · SCYX · Life Sciences
A BARDA contract signed on September 25, 2026, provides up to $214 million in non-dilutive funding to develop SCY-247, the company's second-generation antifungal. The initial base period delivers approximately $18.5 million to move oral and intravenous SCY-247 into a Phase 2 trial for invasive candidiasis. The deal is structured as a cost-share arrangement, with BARDA covering eligible direct and G&A costs. If BARDA exercises all six options, the contract could extend up to ten years and fund development through NDA submission for two indications. This is a major validation for a company with a market cap under $50 million — the potential funding is more than four times the company's current valuation, and it comes without issuing shares. The company reiterated that its SCY-770 ADPKD program and cash runway into 2029 remain unchanged.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCYX was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46M. The 52-week trading range was $3.53 to $9.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.